Platelet adhesion partners at injured vasculature

Platelet adhesion partners at injured vasculature refer to the collective ensemble of receptors and ligands that mediate the initial attachment of platelets to the damaged vessel wall, a process essential for hemostasis (Assay Genie, 2024). This interaction is primarily driven by the binding of the platelet glycoprotein Ib-IX-V complex to von Willebrand factor (vWF) immobilized on exposed subendothelial collagen, particularly under high-shear stress conditions (AHA Journals, 2024). Additionally, direct interactions between platelet receptors such as glycoprotein VI (GPVI) and integrin alpha2beta1 with collagen fibers provide stable anchoring and initiate intracellular signaling pathways (NIH, 2024). These signaling events lead to platelet activation, shape change, and the recruitment of further platelets through the activation of integrin alphaIIbbeta3 (GPIIb/IIIa), which binds fibrinogen to facilitate aggregation (R&D Systems, 2024). Dysregulation of these adhesion partners is a key driver of pathological thrombosis, contributing to myocardial infarction and stroke, while genetic deficiencies result in bleeding disorders like von Willebrand disease and Bernard-Soulier syndrome (NIH, 2024). Consequently, these molecules are significant therapeutic targets; drugs such as caplacizumab target vWF to prevent adhesion, while others like abciximab and glenzocimab inhibit specific glycoprotein receptors to manage thrombotic risk (AHA Journals, 2024). The term encompasses a functional group of proteins rather than a single molecular entity, reflecting the complexity of platelet-vessel wall interactions.

Other names

Platelet adhesion receptorsPlatelet-subendothelium adhesion moleculesHemostatic adhesion partnersPlatelet-vessel wall adhesion complex

Inhibition of von Willebrand factor binding to the GPIb-IX-V complex; Blockade of the GPVI-collagen interaction; Antagonism of the integrin alphaIIbbeta3 receptor to prevent fibrinogen-mediated aggregation; Inhibition of integrin alpha2beta1-collagen binding